Ninlaro (Ixazomib Citrate)

Ixazomib Citrate, the active ingredient in Ninlaro, is a proteasome inhibitor presented as a capsule for oral use. It treats relapsed or refractory multiple myeloma in adult patients when combined with lenalidomide and dexamethasone, helping to control malignant plasma cell growth, and is indicated for patients who have received at least one prior therapy.

GNH USA supplies Ninlaro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Ninlaro (ixazomib citrate) is used in the treatment pathway for plasma‑cell cancers, specifically multiple myeloma that has returned after prior therapy or does not respond to earlier regimens. It is administered orally as part of a three‑drug combination.

Relapsed or refractory multiple myeloma: improves progression‑free survival when used with lenalidomide and dexamethasone in adults who have received prior therapy. Multiple myeloma (relapsed/refractory): contributes to deeper and more durable responses when added to the lenalidomide‑dexamethasone backbone.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools that may require hydration. - Fatigue: reduced energy levels and general tiredness. - Thrombocytopenia: lowered platelet counts increasing bleed risk. - Peripheral neuropathy: tingling or numbness in extremities. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Neutropenia: severe drop in neutrophils leading to infection risk. - Severe infections: opportunistic bacterial or fungal infections. - Pulmonary embolism: blood clot formation in lungs. - Cardiac failure: reduced heart function presenting with dyspnea. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Severe rash or hypersensitivity reactions.

Before initiating therapy, clinicians should assess baseline blood counts and organ function.

- Monitor blood counts: regular CBC to detect cytopenias. - Assess hepatic function: liver enzymes should be checked prior to and during treatment. - Evaluate infection risk: watch for signs of febrile neutropenia. - Use contraception: avoid pregnancy due to unknown fetal risk. - Adjust for renal impairment: dose may need modification in severe renal dysfunction. - Store at below 25°C: keep in the original pack, protect from moisture.

Ixazomib may interact with drugs affecting its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin): may reduce ixazomib exposure. - Strong CYP3A inhibitors (e.g., ketoconazole): may increase ixazomib levels and toxicity. - P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure.

Moderate Interactions (Monitor Closely): - Lenalidomide: additive myelosuppression requires blood count monitoring. - Dexamethasone: may enhance immunosuppression. - Antacids containing aluminum or magnesium: can affect oral absorption; separate dosing recommended.